News | May 18, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
The CDMO upgrade represents a transformational step for Remedium Lifecare
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
Omega 3 oil 18 EPA/12 DHA is highly demanded worldwide for its multiple benefits for human and animal health
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
Overall investment in the US facility is estimated around US$50 million
VITADEETM Green is a 100% plant-based Vitamin D3 suitable for food & nutraceuticals
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Subscribe To Our Newsletter & Stay Updated
